Evraz Plans Key Investment Projects For 2021-26 To Secure EBITDA Growth Of Around $630 Mln

Steel company EVRAZ plc (EVR.L) Wednesday that for 2021-26 period, it is considering several key investment projects with the target to secure EBITDA growth in the amount of around $630 million.

The company is expecting the effect on EBITDA from the Steel segment's sales strategy execution to amount to around $300 million in 2026.

Average annual capital expenditures are expected to be around $1.0 billion per annum in 2021-2026. This includes plans to invest around $200 million in the environmental projects in 2022-2025.

EVRAZ will host its Capital Markets Day today, which will feature the presentation by EVRAZ executives.

The presentation will provide the status of the Potential Demerger of coal assets, an update on ESG targets and initiatives and steel business' growth strategy overview.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT